TriangleHEALTH PROFESSIONAL · SOURCE READING
Adjuvant therapy
Source: Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 2, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Stage II Melanoma / Treatment Options for Stage II Melanoma
Adjuvant therapeutic options are expanding for patients at high risk of recurrence after complete resection. Patients with resected stage IIB or stage IIC melanoma, despite not having lymph node involvement, have a similar risk of recurrence and melanoma-specific death as patients with stage III melanoma. As outlined in the Treatment of Resectable Stage III Melanoma section, the U.S. Food and Drug Administration (FDA) has approved several agents as adjuvant therapy for patients with resected stage III melanoma.
Source links and citations
Continue within this section
Preserved source evidence · Not medical advice